Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Mylan Expands Global Injectable Drugs Market Presence

By BiotechDaily International staff writers
Posted on 19 Mar 2013
Generic pharmaceutical giant Mylan (Pittsburgh, PA, USA) is acquiring the injectable drugs unit of Strides Arcolab (Bangalore, India) for USD 1.6 billion, in a bid to expand its presence in the fast-growing generic injectables market.

The deal for Agila Specialties (Bangalore, India) and its overseas specialties subsidiary, Agila Specialties Asia (Singapore), both wholly owned by Strides Arcolab, ends months of uncertainty regarding its future sale, with reports suggesting Pfizer and Otsuka Holdings as other potential buyers. Under the terms of the agreement, Strides and its subsidiary will receive an aggregate sum of USD 1,600 million in cash on closing, and a potential additional consideration of up to USD 250 million subject to the satisfaction of certain conditions by Strides. The deal is expected to help Mylan, one of the world's largest generic drug makers, double its injectable drugs portfolio.

Mylan is a global pharmaceutical company with a portfolio of over 1,100 generic pharmaceuticals and several brand medications. In addition, it offers a wide range of antiretroviral therapies and operates one of the largest active pharmaceutical ingredient manufacturers. Agila Specialties is a leading global specialty injectables business focused on key domains including oncolytics, penems, penicillin, cephalosporins, and ophthalmics in India and overseas. The company operates from nine world-class global manufacturing facilities, including one of the largest sterile capacities in India and amongst the largest lyophilisation capacities in the world.

“The addition of Agila to Mylan’s existing injectables platform will immediately create a new, powerful global leader in this fast-growing, attractive market segment and accelerate our target of becoming a top-three global player in injectables,” said Heather Bresch, CEO of Mylan. “Agila’s broad product portfolio and pipeline, which is very complementary to Mylan’s, is the result of best-in-class research and development and an industry-leading track record of securing product approvals. Importantly, Agila will bring Mylan one of the most state-of-the-art, high-quality injectables manufacturing platforms in the industry.”

“I am excited by the combination of our Agila business with Mylan as it allows Mylan to leverage its operational base to become a leading global injectables company in the coming years and offers great opportunities to the employees who have made Agila what it is today,” said Arun Kumar, Executive Vice Chairman and Group CEO of Strides Arcolab. “Mylan’s long-standing commitment to quality, its track record of integrity and reliability, and powerful global platform make Mylan the perfect fit for this business, both culturally and from a commercial perspective.”

Related Links:

Mylan
Strides Arcolab
Agila Specialties



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This micrograph depicts the presence of aerobic Gram-negative Neisseria meningitidis diplococcal bacteria; magnification 1150x (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Infection by Meningitis Bacteria Depends on Dimerization State of Certain Host Cell Proteins

A team of molecular microbiologists has untangled the complex three-way interaction between the non-integrin laminin receptor (LAMR1), galectin-3 (Gal-2), and the pathogenic bacterium Neisseria meningitidis.... Read more

Drug Discovery

view channel

Molecule in Green Tea Used as Carrier for Anticancer Proteins

A molecule that is a key ingredient in green tea can be employed as a carrier for anticancer proteins, forming a stable and effective therapeutic nanocomplex. This new discovery could help to construct better drug-delivery systems. Some cancer treatments depend on medication comprising the therapeutic drug and a carrier... Read more

Biochemistry

view channel

Discovery of Pain Receptor on T-cells Could Help Treat Autoimmune Disorders

Researchers have discovered that T-cells are activated by a pain receptor. The new findings revealed that the receptor helps control intestinal inflammation in mice and that its activity can be adjusted, providing a potential new target for treating certain autoimmune disorders, such as Crohn’s disease and possibly multiple... Read more

Lab Technologies

view channel
Image: Yale West Campus is organized into research institutes and core facilities — all designed to promote collaboration and interdisciplinary dialogue (Photo courtesy of Yale University).

American and European Partners Establish a Microscopy Center of Excellence

A prominent American university has announced a partnership agreement with a major European producer of microscopes and imaging tools that will establish a center for the use of cutting-edge imaging technologies... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.